Can a targeted pill stop breast Cancer's return? new trial hopes to find out
NCT ID NCT07190443
First seen Nov 01, 2025 · Last updated Jun 02, 2026 · Updated 32 times
Summary
This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy can prevent breast cancer from coming back in people with HR-positive, HER2-negative breast cancer who have already had a local recurrence. About 290 participants will receive either hormone therapy alone or hormone therapy plus abemaciclib for two years. The study aims to improve long-term control and reduce the risk of distant spread.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.